PacificHealth Laboratories, Inc. company was founded in 1995 and is based in Matawan, New Jersey. PacificHealth Laboratories, Inc. engages in the development, marketing, and sale of protein-based nutritional products for appetite regulation. It principally focuses on sports performance, weight loss, and management of Type II diabetes. The company offers ENDUROX R4, a recovery drink; ACCELERADE, a sports drink; ACCEL GEL, an energy gel; and ENDUROX EXCEL, a dietary supplement. PacificHealth Laboratories sells its products through retail outlets, including GNC, sports specialty stores, independent health food retailers, independent bike retailers, health clubs, catalogs, and Internet sites, as well as through independent distributors.

Lorus Therapeutics isn't talking nonsense, they're talking antisense. The biotechnology firm is developing cancer drugs using antisense technology, which prevents cells from producing disease-causing proteins and may cause fewer side effects than traditional chemotherapies. It is testing its lead candidate in this area, LOR-2040, as a treatment for various blood cancers and solid tumors. Lorus is working in other areas of cancer research as well, developing some traditional therapies, as well as immunotherapies, which stimulate the body's immune system to fight cancer. The company licensed its Virulizin immunotherapy, a potential treatment for pancreatic cancer, to a subsidiary of Zoticon Bioventures in 2008.

Dainippon Sumitomo Pharma (DSP) is Osaka's answer to disease. The Japanese drugmaker produces drugs in a wide range of therapeutic categories including cardiovascular disease, gastrointestinal disorders, and infections. Its products include blood pressure medication Amlodin, digestive tract treatment Gasmotin, and antibiotic Meropen. Subsidiary Sepracordevelops and markets central nervous system and respiratory drugs in North America; its top selling product is insomnia therapy Lunesta. In addition to pharmaceuticals, DSP makes food and feed additives, veterinary drugs, fine chemicals, and diagnostic reagents used in research and clinical laboratories. Sumitomo Chemical owns just over half of DSP.

SurModics, Inc. Company was founded in 1979 and is headquartered in Eden Prairie, Minnesota. SurModics, Inc. engages in the development, manufacture, and sale of surface modification and drug delivery technologies to the healthcare industry. The company operates through four business units: Cardiovascular, Ophthalmology, SurModics Pharmaceuticals, and In Vitro Technologies. The Cardiovascular business unit supports the drug delivery and surface modification needs of cardiovascular customers by providing drug delivery polymers and coating technologies, including advanced lubricity (slippery) coatings that ease placement and maneuverability of medical devices in the body. The Ophthalmology business unit develops drug delivery systems for various drugs and other bioactive agents developed by pharmaceutical and ophthalmology companies for the treatment of serious eye diseases.The SurModics Pharmaceuticals business unit specializes in proprietary injectable microparticles and implants based on biodegradable polymers to provide sustained delivery of drugs, as well as supplies biodegradable polymers to corporate and academic customers. The In Vitro Technologies business unit specializes in in vitro diagnostic products and technologies for the biomedical research and medical diagnostic markets. Its products and technologies include protein stabilization reagents, substrates, recombinant autoimmune antigens, surface chemistry technologies for nucleic acid and protein immobilization, and diagnostic format intellectual property. The company markets its technologies and products through sales professionals, as well as sales and marketing relationships with third-parties worldwide. It has collaboration agreements with Genzyme Corporation to develop novel drug delivery solutions with an initial focus on peptide delivery.

Purdue Pharma L.P. company specializes in developing, manufacturing, and marketing sustained-release and long-acting treatments for chronic and severe pain. Its opioid drugs for pain relief include controlled-release analgesics OxyContin (a version of oxycodone), Ryzolt (tramadol), and morphine drug MS Contin. The company continues to develop and commercialize new products through alliances with such companies as Transcept and Labopharm. Purdue also sells a number of non-prescription products including topical antiseptic Betadine and the Colace and Senokot lines of laxatives. Purdue Pharma operates in the US.

NovaDel Pharma is developing new ways to deliver popular over-the-counter and prescription drugs...just make sure you don't grab your cologne by mistake. NovaDel company's proprietary oral spray delivery system allows for faster absorption into the bloodstream, in turn producing therapeutic benefits more quickly. NovaDel won FDA approval of its first product, NitroMist (an oral spray formulation of a common angina treatment), in 2006; the company is looking for a partner to market the drug. The company received FDA approval of its ZolpiMist, a spray version of Sanofi-Aventis' insomnia drug Ambien, in 2008. It is also developing spray versions of treatments for nausea, migraine, and central nervous system disorders.

The US subsidiary of pharmaceuticals and materials giant Bayer AG (or Bayer Group), Bayer Corporation operates through three divisions and an internal services company. Bayer Corporation handles Bayer Group's US operations in three segments: Bayer HealthCare (pharmaceuticals, animal health, and over-the-counter medicines), MaterialScience (plastics, coatings, and polyurethanes), and Bayer CropScience (herbicides, fungicides, and insecticides). The internal services unit, Bayer Corporate and Business Services, handles administrative, technology, human resources, legal, and procurement functions for the Bayer Group's US operations.

Sino Biopharmaceutical manufactures medicines that combat cardio-cerebral diseases and hepatitis. Incorporated in 2000, Sino markets its products throughout China in the form of volume injections, PVC-free soft bags for intravenous injections, capsules, tablets, powdered medicines, and granulated medicines. It is additionally researching and developing new medicines in the realms of oncology, analgesic, and respiratory treatment. Sino primarily operates through four main subsidiaries: Beijing Tide Pharmaceutical, Jiangsu Chia Tai Tianqing Pharmaceutical, Nanjing Chia Tai Tianqing Pharmaceutical, and Beijing Chia Tai Green Continent Pharmaceutical.

AstraZeneca France does its bit to help its parent, global pharmaceutical powerhouse AstraZeneca, fight diseases from A to Z. In addition to its headquarters at Reuil Malmaison, the company operates an R&D facility for cancer treatments and packaging in Reims. The plant, which produces cancer as well as cardiovascular drugs, sends about a third of its product to Italy, the rest to North Africa and Portugal. The company's Dunkirk production plant makes Pulmicort, Symbicort, Mopral, and INexium in its chemical unit, while the pharmaceutical unit makes Bricanyl and Turbuhaler. Dunkirk ships its finished products to the US. In all AstraZeneca France, which was formed in 1975, makes and ships about 40 drugs.

Banner Pharmacaps, Inc., a drug delivery and specialty pharmaceutical company, engages in the research, development, and manufacture of oral dosage forms for the pharmaceutical health care industry. It develops drug delivery systems and patented technologies, including Soflet Gelcaps, a technology that enrobes tablets with a gelatin or non-animal film; LiquiSoftT Chewable Liquid-Filled Softgels, which is a chewable gel dosage form suitable for pediatric populations; Chewel, a soft chewable gelatin dosage form for pediatric populations; EnteriCare, which are enteric softgels; Versatrol, which is a controlled release softgel technology; and EcoCaps, which are non-animal softgels. It serves pharmaceutical and biotechnology, and consumer healthcare markets. The company was founded in 1994 and is headquartered in High Point, North Carolina. It has drug manufacturing facilities in High Point, North Carolina; Tilburg, the Netherlands; Olds, Canada; and Mexico City, Mexico. It has locations in Mexico, Europe, the Asia/Pacific, the United States, and Canada. Banner Pharmacaps, Inc. operates as a subsidiary of VION N.V.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.